Cargando…
1571. BIC/FTC/TAF in Virologically Suppressed PLWHIV: 48-96 weeks RETROBIC Multicenter Cohort study results.
BACKGROUND: Switching strategy with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) has become a gold standard for people with HIV (PLWHIV) with high efficacy and safety rates in long-term data of pivotal clinical trials. However, data regarding immune status restoration in real-life c...
Autores principales: | Estévez, Samuel, Buzón, Luis, Pousada, Guillermo, Tomé, Roberto Pedrero, Galera, Carlos, Sanz, Jose, Santos, Ignacio, Dueñas, Carlos, Cabello, Noemí, Martín, Cristina, Galindo, María José, Garcinuño, María Ángeles, Hernández, Cristina, Lebón, Gabriela, Fernández, Beatriz, Troya, Jesús |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678094/ http://dx.doi.org/10.1093/ofid/ofad500.1406 |
Ejemplares similares
-
1598. Predictive equations for immune recovery at 48 weeks of BIC/FTC/TAF treatment in Virologically Suppressed PLWHIV.
por: Tomé, Roberto Pedrero, et al.
Publicado: (2023) -
Predict the Effects of Dolutegravir (DTG) Plus Lamivudine (3TC) on Immunological Responses in People Living with HIV (PLWHIV)
por: Troya, Jesús, et al.
Publicado: (2023) -
Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study
por: Hayes, Edwin, et al.
Publicado: (2020) -
2508. Virologic Suppression in Patients Switched to BIC/TAF/FTC with Baseline NRTI and/or INSTI Resistance
por: Natali, Kayla M, et al.
Publicado: (2019) -
Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic
por: Buzón, Luis, et al.
Publicado: (2023)